We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

55 hedge funds and large institutions have $204M invested in Intra-Cellular Therapies Inc. in 2014 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

263% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 8

129% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 7

57% more funds holding

Funds holding: 35 → 55 (+20)

2% more capital invested

Capital invested by funds: $201M → $204M (+$3.12M)

Holders
55
Holders Change
+20
Holders Change %
+57.14%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
16
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$6.97M
2
BIT
BlackRock Institutional Trust
California
+$3.2M
3
State Street
State Street
Massachusetts
+$2.59M
4
Morgan Stanley
Morgan Stanley
New York
+$1.96M
5
BIM
BlackRock Investment Management
Delaware
+$1.8M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$4.08M
2
DM
Deerfield Management
New York
-$3.12M
3
AC
Ascend Capital
California
-$1.48M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.14M
5
HCMT
Highland Capital Management (Texas)
Texas
-$487K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$737K +$408K +24,716 +130%
Deutsche Bank
27
Deutsche Bank
Germany
$550K -$287K -17,335 -35%
California State Teachers Retirement System (CalSTRS)
28
California State Teachers Retirement System (CalSTRS)
California
$526K +$516K +31,200 New
Goldman Sachs
29
Goldman Sachs
New York
$434K +$425K +25,729 New
TA
30
Teachers Advisors
New York
$406K +$398K +24,080 New
CS
31
Credit Suisse
Switzerland
$344K -$262K -15,873 -44%
TC
32
TFS Capital
Pennsylvania
$329K +$323K +19,533 New
MLICM
33
Metropolitan Life Insurance Company (MetLife)
New York
$313K +$307K +18,580 New
SG Americas Securities
34
SG Americas Securities
New York
$300K +$294K +17,816 New
First Eagle Investment Management
35
First Eagle Investment Management
New York
$295K +$289K +17,500 New
Millennium Management
36
Millennium Management
New York
$290K +$23K +1,391 +9%
Swiss National Bank
37
Swiss National Bank
Switzerland
$287K +$281K +17,000 New
NFA
38
Nationwide Fund Advisors
Ohio
$218K +$214K +12,924 New
VOYA Investment Management
39
VOYA Investment Management
Georgia
$208K +$204K +12,331 New
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$198K +$194K +11,730 New
PAM
41
Panagora Asset Management
Massachusetts
$193K +$189K +11,424 New
AIG
42
American International Group
New York
$189K +$185K +11,185 New
ST
43
Stifel Trust
Missouri
$186K +$140K +8,500 +340%
Jane Street
44
Jane Street
New York
$185K +$182K +11,000 New
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$182K +$178K +10,762 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$172K +$168K +10,181 New
Bank of America
47
Bank of America
North Carolina
$74K +$72.7K +4,396 New
TRCT
48
Tower Research Capital (TRC)
New York
$64K +$53.1K +3,213 +542%
BRWA
49
B. Riley Wealth Advisors
Florida
$42.1K +$41.3K +2,500 New
AllianceBernstein
50
AllianceBernstein
Tennessee
$40K +$39.7K +2,400 New
1
2
3

ITCI Hedge Fund Activity: Q2 2014 in Review

55 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2014, worth a combined $204M — up 1.6% from $201M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ITCI positions and 8 closed out — a net gain of 21 holders — while 16 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock Fund Advisors, opening a new position worth an estimated $6.97M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.08M sold.

  • 55 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2014, up from 35 in Q1 2014.
  • Funds reported $204M of Intra-Cellular Therapies Inc. stock for Q2 2014, up 1.6% quarter-over-quarter.
  • 29 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2014 and 8 closed out, a net change of +21 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $6.97M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2014 was Broadfin Capital, an estimated $4.08M sold.

Based on aggregated 13F filings for Q2 2014.